- Conditions
- Chronic Kidney Disease
- Interventions
- Group 2: Dasatinib, Group 2: Quercetin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 7:59 PM EDT